Catalyst Pharmaceuticals (NASDAQ: CPRX) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Catalyst Pharmaceuticals to related businesses based on the strength of its dividends, institutional ownership, earnings, valuation, analyst recommendations, profitability and risk.
Insider & Institutional Ownership
40.1% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 50.5% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 8.8% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Catalyst Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
Volatility and Risk
Catalyst Pharmaceuticals has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals’ competitors have a beta of 6.66, meaning that their average stock price is 566% more volatile than the S&P 500.
This is a summary of recent ratings for Catalyst Pharmaceuticals and its competitors, as provided by MarketBeat.
Catalyst Pharmaceuticals presently has a consensus price target of $5.50, suggesting a potential upside of 91.64%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.14%. Given Catalyst Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Catalyst Pharmaceuticals is more favorable than its competitors.
Earnings and Valuation
This table compares Catalyst Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.
Catalyst Pharmaceuticals’ competitors have higher revenue and earnings than Catalyst Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy.